drugset / Trial / NCT03331848

Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

NCT03331848

Phase 2 Withdrawn Prexton Therapeutics
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing Motor Complications of Levodopa Therapy

Timeline

Start
2018-01-15
Primary completion
2019-02-01
Completion
2019-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Foliglurax Small molecule 20 mg Oral

Indications